DE602005021534D1 - Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung - Google Patents

Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung

Info

Publication number
DE602005021534D1
DE602005021534D1 DE602005021534T DE602005021534T DE602005021534D1 DE 602005021534 D1 DE602005021534 D1 DE 602005021534D1 DE 602005021534 T DE602005021534 T DE 602005021534T DE 602005021534 T DE602005021534 T DE 602005021534T DE 602005021534 D1 DE602005021534 D1 DE 602005021534D1
Authority
DE
Germany
Prior art keywords
peptides
amphipathic
multidomade
helixful
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021534T
Other languages
English (en)
Inventor
Alan T Remaley
Stephen J Demosky
John A Stonik
Marcele J A Amar
Edward B Neufeld
Bryan H Brewer
Fairwell Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE602005021534D1 publication Critical patent/DE602005021534D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Materials For Medical Uses (AREA)
DE602005021534T 2004-10-15 2005-10-14 Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung Active DE602005021534D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61939204P 2004-10-15 2004-10-15
PCT/US2005/036933 WO2006044596A2 (en) 2004-10-15 2005-10-14 Multi-domain amphipathic helical peptides and methods of their use

Publications (1)

Publication Number Publication Date
DE602005021534D1 true DE602005021534D1 (de) 2010-07-08

Family

ID=36203530

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021534T Active DE602005021534D1 (de) 2004-10-15 2005-10-14 Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung

Country Status (9)

Country Link
US (4) US7572771B1 (de)
EP (2) EP2218736A1 (de)
JP (1) JP5091679B2 (de)
AT (1) ATE469174T1 (de)
AU (1) AU2005295640B2 (de)
CA (1) CA2584048C (de)
DE (1) DE602005021534D1 (de)
ES (1) ES2346771T3 (de)
WO (1) WO2006044596A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20110059549A1 (en) 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
US8936787B2 (en) 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
WO2010020822A1 (en) * 2008-08-19 2010-02-25 University Of Patras Therapy for apolipoprotein-induced hypertriglyceridemia
US10151037B2 (en) 2009-01-12 2018-12-11 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide dependent target reduction, and related methods and systems
WO2011066511A1 (en) 2009-11-30 2011-06-03 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
EA034702B1 (ru) * 2011-04-26 2020-03-10 Молекулар Экспресс, Инк. Липосомные композиции
EP2701725A1 (de) 2011-04-29 2014-03-05 Kinemed, Inc. Chemische modifizierung von mimetischen apolipoproteinpeptiden zur herstellung von therapeutika
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
AU2013299641A1 (en) 2012-08-10 2015-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
CN104755618A (zh) 2012-08-16 2015-07-01 合成基因组股份有限公司 数字生物转化器
WO2015057583A1 (en) 2013-10-14 2015-04-23 The United States Of America, As Represented By The Secretary Treatment of chronic kidney disease with sahps
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
US20160074473A1 (en) 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US11529390B2 (en) * 2015-03-19 2022-12-20 Institut De Cardiologie De Montreal PCSK9 inhibitory polypolypeptides and methods of use
WO2017044899A1 (en) * 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
EP3490579A1 (de) 2016-07-27 2019-06-05 Hartis-Pharma SA Therapeutische kombinationen zur behandlung von erythrozytendysfunktionen
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3436928A1 (de) * 1984-10-09 1986-04-10 Siegel, Rolf, Dr., 8700 Würzburg Alloplastische gefaessprothese, verfahren zu deren herstellung
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
DE69321118T2 (de) 1992-06-12 1999-06-02 Naamloze Vennootschap Innogenetics S.A., Gent Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer
AU6059898A (en) * 1996-09-05 1998-03-26 Uab Research Foundation, The Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7205280B2 (en) 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
JP2003529375A (ja) 2000-03-31 2003-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト動脈壁細胞内で酸化脂質により誘発される遺伝子の制御
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
EP2382983B1 (de) 2004-09-02 2014-02-12 Cognosci, Inc. Verbesserte ApoE-Analoga und Verwendungsverfahren dafür
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
US8710429B2 (en) 2007-12-21 2014-04-29 The Board Of Regents Of The University Of Ok Identification of biomarkers in biological samples and methods of using same

Also Published As

Publication number Publication date
US8071746B2 (en) 2011-12-06
US7572771B1 (en) 2009-08-11
CA2584048A1 (en) 2006-04-27
WO2006044596A8 (en) 2006-06-29
US20090270331A1 (en) 2009-10-29
AU2005295640B2 (en) 2011-07-28
EP1812474B1 (de) 2010-05-26
CA2584048C (en) 2016-08-09
US20100203099A1 (en) 2010-08-12
JP5091679B2 (ja) 2012-12-05
ATE469174T1 (de) 2010-06-15
JP2008516605A (ja) 2008-05-22
AU2005295640A1 (en) 2006-04-27
ES2346771T3 (es) 2010-10-20
WO2006044596A3 (en) 2006-09-08
EP1812474A2 (de) 2007-08-01
WO2006044596A2 (en) 2006-04-27
EP2218736A1 (de) 2010-08-18
AU2005295640A2 (en) 2006-04-27
US8148323B2 (en) 2012-04-03
US8835378B2 (en) 2014-09-16
US20120148642A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
DE602005021534D1 (de) Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
DE602004022424D1 (de) Proteasominhibitoren und verfahren zu deren anwendung
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
ATE459621T1 (de) Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung
DK1766077T3 (da) Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
ATE404188T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
DE602006012513D1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
DE602005026398D1 (de) System zur abgabe von flüchtigen stoffen
BR0315689A (pt) Alvo para terapia de dano cognitivo
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE398921T1 (de) Modulare anordnung und verfahren zum züchten von wassertieren
DE50010875D1 (de) Verfahren zum einspritzen von kraftstoff und einspritzventil zur durchführung des verfahrens
DE602004017283D1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
ATE519504T1 (de) Chromatin-remodellierende substanzen zur erhöhung der expression von pdx-1 und förderung der zelldifferenzierung
TR199902192T2 (xx) Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
DE602006016413D1 (de) Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition